CA1188614A - Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose - Google Patents

Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose

Info

Publication number
CA1188614A
CA1188614A CA000423322A CA423322A CA1188614A CA 1188614 A CA1188614 A CA 1188614A CA 000423322 A CA000423322 A CA 000423322A CA 423322 A CA423322 A CA 423322A CA 1188614 A CA1188614 A CA 1188614A
Authority
CA
Canada
Prior art keywords
tablets
weight
methocel
mixture
base material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000423322A
Other languages
French (fr)
Inventor
Norman G. Gaylord
Joseph M. Schor
Ashok Nigalaye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forest Laboratories LLC
Original Assignee
Forest Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories LLC filed Critical Forest Laboratories LLC
Application granted granted Critical
Publication of CA1188614A publication Critical patent/CA1188614A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

SUSTAINED RELEASE THERAPEUTIC COMPOSITIONS BASED ON
HIGH MOLECULAR WEIGHT HYDROXYPROPYLMETHYLCELLULOSE

ABSTRACT

A carrier base material combined with a therapeutically active medicament and shaped and compressed to a solid unit dosage form having a regular and prolonged release pattern upon administration, the carrier base material being one or more hydroxypropylmethylcelluloses or a mixture of one or more hydroxypropylmethylcelluloses and up to 30% by weight of the mixture of methylcellulose, sodium carboxymethylcellulose and/or other cellulose ether, and wherein at least one of the hydroxypropylmethyl-celluloses has a methoxy content of 16-24 weight-%, a hydroxypropoxyl content of 4-32 weight-% and a number average molecular weight of at least 50,000 and wherein the carrier base material constitutes less than about one third of the weight of the solid unit dosage form.

Description

SUSTAINED RELEASE THERAPEU'rIC COMPOSITIONS BASED ON HIGH
MOLECULAR WEIG`HT HYDROXYPROP~LMETHYLCELLULOSE

BACKGROUND OF THE INVENTION

1. Field of Invention This invention relates to a carrier base material to be combined with a therapeutically active medicament and formed into a solid, shaped dosage unit having a long-lasting and regular incremental release o:E the medicament upon admin~
istration. Specifically, this invention relates to a carrier 10 base material, consisting essentially or predominantly of hydroxypropylmethylcellulose having a chemical structure and molecular weight which renders it sui~able for use, in relatively low concentrations, in sustained release therapeutic compositions.
2. Description of the Prior Art Hydroxypropylmethylcelluloses are commercially avail-able in various grades, under several tradenames, including Methocel E, F, J and K (registered trademarks and all previously designated as Methocel HG) from The Dow Chemical Co.s U.S.A., HPM, a registered trademark of and from British Celanese Ltd., England, and Metalose SH, a registered trade-mark of and from Shin-Etsu, Ltd., Japan. The various grades available under a given tradename represent differences in methoxyl and hydroxypropoxyl content as well as molecular weight. The methoxyl con~ent ranges from 16.5 to 30 weight-~/O
and the hydroxypropoxyl content ranges from 4 to 32 weight-%, as determined by the method described in ASTM D-2363-72.

-1- ~

, ~ 3~ ~ ~
Commercial designatlons of the various hydroxy-propylmethylcelluloses are based on the viscosities of 2%
aqueous so]utions at 20C. The viscositi.es range :Erom 15 cps to 30,000 cps and represent number average molecular weights ranging from about 10,000 to over 150,000, as calculated from the data in "Handbook of Methocel Cellulose Ether Products" (The Dow Chemical Co., 1974).
A solid unit dosage form consisting of a mixture of a medicament and a carrier base material which is low molecular weight hydroxypropylmethylcellulose Methocel E50, formerly known as Methocel 601~G 50 cps, having a number avera,~e molecular weight of 23,000, a methoxyl content of 28-30 weight-%, and a hydroxypropoxyl content of less than 9 weight-%, rapidly releases the medicament when brought into contact with the aqueous fluids of the mouth or the gastrointestinal tract.
~owever, an effective "sustained release" tablet is produced by admixture of a medicament with a modified Methocel E50, per se or in admixture with other cellulose ethers. As disclosed by Lowey and Stafford (U.S. Patent 3,870,790) and Schor (U.S. Patent 4,226,849), the modification is carried out by exposure of the low molecular weight hydroxypropyl-methylcellulose Methocel ~50 to high humidity or moisture and drying in air.
It has been disclosed in U.S. Patent No. 4,369,172 that effective prolonged release therapeutic compositions may be prepared by using as a carrier base material a hydroxypropylmethylcellulose having a hydroxypropoxyl content of 9-12 weight-%, and a number average molecular weight of less than 50,000) e.g.
Metalose 60S~150. The carrier base material provides sustained release characteristics without treatment or modification.
Christenson and Huber (U.S. Patent 3,590,117) reported that high viscosity grade, i.e. 15,000 cps, hydroxypropylmethylcellulose did not make an acceptable long-lasting troche because the troche would flake off in the mouth rather than dissolve uniformly.
Christenson and Dale (U.S. Patent 3,065,143) disclosed the use of certain high molecular weight hydro-philic gums, including hydroxypropylmethylcelluloses, in the preparation of a "sustained release tablet". The tablet consisted essentially of a mixture of a medicament and at least one third part be weight of the weight of the tablet of a hydrophilic gum which rapidly absorbed water and swelled at 37C to form a "soft mucilaginous gel barrier" on the surface of the tablet when brought into contact with the aqueous fluids of the gastrointestinal tract.
The high molecular weight hydroxypropylmethyl-celluloses disclosed by Christenson and Dale and constituting at least one third of the weigllt of the tablet, include Methocel 60HG 4000 cps, now known as Methocel E4M, having a 28-30 weight-C/O methoxyl content. a 7.5 12 weigh~-% hydroxy-propoxyl content and a number average molecular weight of 93,000, and Methocel 90HG 4000 cps and Methocel 90HG 15,000 cps, now known as Methocel K4M and Methocel K15M, respectively.
The latter have number average molecular weights of 89,000 and 124,000, respectively, and a 19-24 weight-% methoxyl content, and a ~-12 welght-% hydroxypropoxyl content.
The present invention is dlrected ~oward further improvements in carrier base materials containing hydroxy-propylmethylcelluloses for use in the preparation of sustained release solid pharrnaceutical unit dosage forms, particularly with moisture sensitive and/or high dosage medicaments.

SUMMARY OF THE II~VE~ilTIO~

An object of the present inventlon is to provide a carrier material for use in the preparation of orally, bucally or sublingually, etc., administered lozenges and tablets, as well as suppositories and other solid unit dosage forms which have a regular and sustained release pattern for a systemically absorbable medicament or active ingredient incorporated therein.
Another object of the present lnvention is to provide a carrier base having greater stability, greater hardness, lower friability, reduced water solubility and a uniform sustained release pattern from hydroxypropylmethylcellulose, particularly for use with moisture sensi.tive medicaments.
A furtler object of the present invention is to provide a carrier base which comprises less than about 30 weight-% of the weight of the solid unit dosage form, permitting the preparation of smaller units which are easier to administer.
Still another object of the present invention is to provide a carrier base for use with high dosage medicaments in sustained release dosage forms.
It has now been found that these improvements in a carrier base can be achieved by utilizing a high viscosity grade hydroxypropylmethylcellulose having a number average molecular weight above 50,000 and a methoxyl content of 16-24 weight-%, wherein said carrier base constitutes less than about one third of the weight of the sustained release dosage form.

DETAILED DESCRIPTION OF THE INVENTION

10 According to the present invention, it has now been found that important advantages and improvements over prior products containing hydroxypropylmethylcelluloses, as described in U.S. Patents 3,065,143, 3,870,790 and 4,226,~49, can be obtained by utilizing a high viscosity grade hydroxypropyl-mehtylcellulose having a methoxyl content of 16-24 weight-~The hydroxypropylmethylcellulose used in the present invention has a number average molecular weight above 50,00 and a hydroxypropoxyl content of 4-32 weight-%.
The hydroxypropylmethylcelluloses which are effective in the present invention include, but are not limited to, commercially available 4000 and 15,000 cps viscosity grades of Methocel K, i.e. Methocel K4M and Methocel K15M, available from the Dow Chemical Co., U.S.A., and 4000, 15,000 and 30,000 cps viscosity grades of Metalose 90SH, available from Shin-Etsu Ltd., Japan, as well as 5,000, 12,000, 20,000 and 75,000 cps viscosity grades of Methocel J, i.e. Methocel J5M, J12M, J20M and J75M, available from the Dow Chemical Co.
Althougl. U.S. 3,065,143 disclosed that a sustained release tablet required the presence of at least one third of the weight of the tablet of these hydroxypropylmethyl-celluloses, it has surprisingly been found that e:Efectivesustained release can be obtained from solid dosage forms containing as llttle as 5 to about 30 weight-% of these hydroxypropylmethylcelluloses.
Numerous advantages result from the ability to use less than about 30~/O of the carrier base material in a sustained release dosage form. These include the use of smaller tablets which are more economical and are easy to administer. High dosage drugs which normally result in large tablets can be put in smaller sustained-release dosage form.
Cellulose ethers such as the hydroxypropylmethyl-celluloses of the present invention are hydrophilic and tend to ahsorb moisture from the atmosphere. The use of low levels of the cellulose ether in a solid dosage form results in a lower moisture content upon exposure to the atmosphere.
This is particularly important when the active medicament is mo~sture sensitive and undergoes decomposition and/or hydrolysis upon contact with moisture. Typical moisture sensitive drugs include aspirin, phenacetin, procainamide, nikethamide, poly-mixin, barbiturates, idoxuridine, hydantoins, angiotensinamide, nitroglycerin, benzocaine, scopolamine, meperidine, codeine, streptomycin, ascorbic acld, sulfonamide drugs, tolbutamide, antihistamine salts such as chlorpheniramine and brompheni-ramine, phenylephrine, diphenhydramine, diethylcarbamazine, theophylline, caffeine, alkaloi~ salts, adrenocortical steroidesters such as hydrocortisone phosphate, and the like.
The hydroxypropylmethylceIluloses of the present invention may be used without prior humidification or similar treatment and when mixed with an active medicament, the mixture has excellent compressibility and the tablets prepared therefrom are hard and dense,have low friability andprovide sustained release over an extended period. Treatment of the carrier base material by humidification and drying before incorporation in a sustained release tablet has little or no effect on the compressibility of the polymer and the properties of the tablets prepared therefrom.
Sustained release drug forms containing the hydroxy-propylmethylcelluloses of the present invention are stable and the release rate does not change over an extended storage period. The therapeutic compositions of the present invention, in most cases, give a steady, reproducible release of the active medicament.
A hydroxypropylmethylcellulose having a methoxyl content of 16-24 weight-% and a number average molecular weight above 50,000 can be used as the sole carrier base material or can be used in admixture in all proportions with other hydroxy-propylmethylcelluloses of the same structure with a higher or a lower but above 50,000 number average molecular weight, e.g.
a 30/70 or 70/30 mixture of Methocel K~M and Methocel K15M. A
hydroxypropylmethylcellulose having a different structure and a number average molecular weight above 50,000 can also be used in admixture with the high molecular weight hydroxypropyl-methylcellulose having a methoxyl content of 1~-2~ weight-a/O, e.g. a 30/70 or 50/50 mixture of Methocel E4M and Methocel K4M.
The hydroxypropylmethylcelluloses of the present invention can be optionally mixed with about 0 to 30% by weight of the mixture of a hydroxypropyl.methylcellulose with the same or dlfferent structure and a number average molecular weight below 50,000, or methylcellulose, sodium carboxymethyl-cellulose or other cellulose ether.
The active ingredient can be of any type of medication which acts locally in the mouth or systemically, which in the case of the latter, can be administered orally to transmit the active medicament into the gastrointestinal tract and into the blood, fluids and tissues of the body without excessive peak concentrations occurring. Alternatively, the active ingredient can be of any type of medication which acts through the buccal tissues of the mouth to transmit the active ingredient directly into the blood stream thus avoiding first pass liver metabolism and by-passing the gastric and intestinal fluids which have an adverse inactivating or destructive action on many active in-gredients unless they are especially protected against such fluids as by means of an enteric coating or the like. The active ingredient can also be of a type of medication which can be transmitted into the blood circulation through the rectal tissues.
Representative active medicaments include antacids, anti-inflammatory substances, coronary vasodilators, cerebral vasodilators, peripheral vasodilators, anti-infectives, psycho-tropics, antimanics, stimulants, antihistamines, laxatives, decongestants, vi-tamins, gastro-intestinal sedatives, anti-cliarrheal preparations, anti-anginal drugs, vasodilators, antiarrythmics, anti-hypertensive drugs, vasoconstrictors and migraine treatments, anticoagulants and antithrombotic drugs, analgesics, anti-pyretics, hypnotics, sedatives, anti-emetics, anti-nauseants, anticonvulsants, neruomuscular drugs, hyper- and hypoglycaemic agents, thyroid and anti-thyroid preparations, diuretics, antispasmodics, uterine relaxants, mineral and nutritional additives, antiobesity drugs, ana~olic drugs, erythropoietic drugs, antiasthmatics, expectorants, cou~h suppressants, mucolytics, antiuricemic drugs, and other drugs or substances acting locally in the mouth, such as topical analgesics, local anaesthetics, etc.
The hydroxypropylmethylcelluloses of the present invention are partucularly effective in the preparation of sustalned release unit dosage forms containing moisture sensitive medicaments such as those named earlier. However, it is to be understood that the invention is applicable to sublingual lozenges, suppositories and compressed tablets, the latter intended to be swallowed in unit dosage form and which upon ingestion according to a prescribed regimen give slow and regular release of active medicament while being protected against normally inactivating gastric Eluids.
The hydroxypropylmethylcellulose having a methoxyl content of 16-2~ weight-%, a number average molecular weight of more than 50,000 and present in a concentration of less than about one-third of the total weight of the dosage form, forms what is called a long-acting, slow dissolving carrier of such a nature that it has a protective, demulcent and buffering effect in the body and causes the active medicament ~ ~ ~~
to exert its optimum therapewtic action iLnmediately and in-crementally for many hours, so that full therapeutic acdvantage can be taken of the entire or substantially the entire amount of active medicament administered. This unexpectedly high degree of efficiency is a particular advantage of the in-vention and minimizes the side effects of the medication.
In making up tablets containing an orally administrable systemi.cally absorbable active component such as one of the neretofore mentioned medicaments, the oral carrier material is thoroughly intermixed with the medicament which is also in powdered or granular form or in solution, and any other needed ingredien-ts which are conventional in tablet making such as magnesium stearate, lactose, starch and, in general, binders, fillers, disintegrating agents and the like. The complete mixture, in an amount sufficient to make a uniform batch of tablets, e.g. 50,000, of which each contains an effective amount of active medicament, is then subjected to tableting in conventional tableting machines at compression pressures of 2,000 to 16,000 lbs/sq.in. and, because of the use of the specific carrier material of this invention in the production of the tablets, a product is obtained which has the desired hardness, low level of friability and a predetermined prolonged action and a regular delayed release pattern so that the medicament is available over a period of 1 to 36 hours, depending on the precise tablet size, hardness and the par-ticular carrier composition. In this way, it is possible to produce sustained or slow continuous release tablets in relatively simple and economical manner on a commercial scale as contrasted with the more elaborate and more complex materials and procedures heretofore employed or proposed.
The moisture content o:E the carrier used in the preparati.on of the sustained release tablets may be in the 0.1-10% range, the lower end of the range being preerable when moisture sensitive medicaments are used. If the moisture con-tent is outside o:E this range, it may be brought within the range by the use of ambient or hot, dry or wet air, using appropriate equipment including static, convection, forced air or vacuum chambers or other equipment well known to those skilled in the art. The moisture content of the carrier during tableting influences the integrity of the tablet obtained under a given compression pressure. ~owever, the moisture content has little or no influence on the sustained release characteristics and plays a minor role as compared to the chemical structure of the carrier and its concentration on the ra~e of release of medicaments. Similarly, while the release rate is governed at least in part by the size of the tablet or other shaped dosage form, as well as by the degree of compression, the chemical structure of the hydroxypropylmethylcellulose superimposes its effect and is the dominant factor in the control of the release rate.
The relea&e pattern of active medicament from the carrier of the present invention can be controlled according to the particular medication and its intended therapeutic effect. For a sublingual lozenge or tablet, the release pattern may be varied from about 15 minutes to 4 hours. For orally administered tablets, the rate of release may be 2-4 hours, 4-8 hours, 8-10 hours, 10-12 hours, 15-18 hours, 20-24 hours, etc., as desired. For vaginal and rectal suppositories, the release pattern ranges from 2 to 36 hours, and can be less where indicated. Predetermined release patterns of unusually reliable and constant characteristics can be secured. This is often very important medically, especially when treating patients having coronary diseases, such as angina pectoris with nitroglycerin, or related problems of circulatory disorders or abnormal blood pressure conditions or psychotropic disorders such as manic depression or schizophrenia. The invention is particularly important also in treating such conditions as ulcerated tissue or mucous lesions and other conditions which arise from local hyperacidity or metabolic dysfunction in the physiological system. The invention is therefore of very versatile and adaptable nature giving it a wide range o~ application and end use.
The following illustrative embodiments of the dis-closures of ~he present invention are non-limiting and variations will be obvious to those skilled in the art.

Examples 1-6 describe the preparation of controlled release 650 mg aspirin tablets.

Controlled release 650 mg aspirin tablets containing 13.2% Methocel K4M were prepared from untreated Methocel K4M
having a moisture content of 2.5% and from treated Methocel K4M
which had been exposed to 85% humidity for 24 hours and then dried in a forced air oven at 120F to a moisture content of 5.0%.
The 650 mg aspirin tablets were prepared from the following ingredients:

Ingredients grams mg/tablet 1 Aspirin (40 mesh) 1300 650 2 Methocel K4M 200 100 15 3 Hydrogenated vegetable oi]
(Lubritab) Registered Trademark 14 7 4 Fumed silica (Cab-O-Sil M-5) Registered Trademark 1 0.5 Ingredients 1 and 2 were mixed, ingredient 3 was added to the blend and, after mixing, was followed by ingred-ient 4. The mixture was blended for 20 minutes and then sub-jected to compression in a tableting machine having a 0.281x0.625 inch punch, under a compression pressure of 4000 psi, to make 2000 capsule shaped tablets bisected on one side. The average weight of the tablets was 760 mg from untreated Methocel K4M

and 750 mg from treated Methocel K4M. The thickness of the tablets was 0.265-0.280 inches from the former and 0.260-0.265 inches from the latter.
The hardness of the tablets was determined on a Penn-walt Stokes hardness tester. The friability was determined in an Erweka Friabilator (Erweka-Apparatebau GmbH, Heuenstamm Kr.
Offenbach/MainJ West Germany) by measuring the weight loss after
3 minutes rotation.
The release rate was determined by using the release rate apparatus as described in NF XIV, page 935. Five tablets were plac~d into a 100 ml screw cap dissolution vial and 60 ml of a buffered solution of the desired pH, preheated to 37C, was added to the vial. The vial was closed and rotated in the NF
time release apparatus maintained at 40 + 2 rpm. At intervals of one hour, the vial was opened and the supernatant liquid was poured through a screen and collected. The collected liquid was quantitatively transferred to a 100 ml volumetric flask.
The tablets on the screen and the vial were washed with deionized water, the washings being added to the flask. The washed tablets were returned to the vial from the screen with the aid of the next buffered solution and the closed vial was rotated in the bath for the next interval of one hour. The following schedule of buffered solutions was used:

- -Hours pH Hours pH

1 1.2 9 7.5 2 2.5 ~ 10 7.5 3 4.5 ~ 11 7.5
4 ~.5 12 7.5 7.0 13 7.5 6 7.0 14 7.5 7 7.5 15 7.5 8 7.5 16 7.5 The solutions separated from the tablets were analyzed for the concentration of medicament released from the tablets.
The procedure was continued until at least 90~/O of the tablet had dissolved and/or essentially all of the medicament had be~n released.
The 650 mg aspirin tablets had the following properties:

- ~ -Example No. 1 ~ 2 _ Methocel K4M Untreated Treated Hardness, kg 7.5-8.5 9.0-10.0 Friabillty, % 0.4 0.26
5 Release rate Cumulative Cumulative Hour ~/O % % %
1 8.9 8.9 10.8 10.8 2 11.6 20.5 ~10.8 21.6 3 10.6 31.1 ~12.0 33.6 4 10.2 41.3 10.7 4~.3 12.~ 53.7 13.5 57.8
6 8.3 62.0 10.7 68.5
7 13.6 75.6 9.~ 77.9
8 7.5 ~3.1 5.5 83.4
9 3.8 86.9 4.3 87.7 3.0 89.9 3.3 91.0 13 _ _ - 98.1 14 _ 100.9 Although the controlled release tablets prepared with treated and untreated Methocel K4M had comparable properties and reIease rates, the storage stability of the aspirin made with the treated carrier base material was about 18 months while that made with the untreated carrier base materlal was more than 3 years.

t~

Controlled release 650 mg aspirin tablets containing 9.0% Methocel K4M were prepared from treated Methocel K4M which had been exposed to 85% humldity for 24 hours and then dried in a forced air oven at 120F to a moisture content of 5.0% and from treated Methocel K4M which was dried in an oven at 210F
to a moisture content of 2.3%
The 650 mg aspi.rin tablets were prepared from the :Eollowing ingredients:

.. .. _ Treated Treated Dried Methocel Methocel Ingredients grams grams mg/tablet -1 Aspirin (40 mesh)6500 650 650 2 Methocel K4M 650 65 65 3 Lubritab 70 7 7 4 Cab-O-Sil M-5 5 0.5 0.5 The ingredients were mixed in the same manner as in Examples 1-2. The mixture was subjected to compression in a tableting machine having a 0.281x0.625 inch punch under a com-pression pressure of 4000 psi to make 10,000 capsule shaped tablets bisected on one side from the treated Methocel K4M and 1000 capsule shaped tablets from the treated and dried Methocel K4M.

The tablets from the treated Methocel K4M had an average weight of 724 mg and a thickness of 0.250-0.260 inches while the tablets from the treated and dried Methocel K4M had an average weight of 714 mg and a thickness of 0.250-0.260 inches.
The hardness, friability and release rate o:E the 650 mg aspirin tablets were determined as described earlier to give the following results:

__ Example No. 3 Methocel K4M Treated TrQated-Dried Hardness, kg 8.0-10.0 7.0-8.0 Friability, % 0.2 0.48 Release rate Cumulative Cumulative Hour ~ % % %

1 12.5 1205 10.7 10.7 2 12.5 25.0 12.1 22.8 3 12.5 37.5 14.4 37.2 4 12.5 50.0 13.2 50.4 15.4 65.~ 16.7 67.1 6 ~10.5 75.9 12.8 79.9 7 111.0 86.9 11.6 91.5 8 5.~ 92.3 4.9 96.4 9 2.8 95.1 3.1 99.5 ~, - ~:L~
EX~PLE 5 Controlled release 650 mg aspirin tablets containing 2.7% Methocel E4M and 6.3% Methocel K4M were prepared from untreated hydroxypropylmethylcelluloses with moist~re coT~tents in the range o:f 2-3%.
The 650 mg aspirin tablets were prepared from the following ingredients:

IngredienTs grams mg/tablet .
1 Aspirin 650 650
10 2 Methocel E4M 19.5 19.5 3 Methocel K4M 45.5 45.5 4 Lubritab 7 7 Cab-0-Sil M-5 0.5 0.5 Ingredient 1 was placed in a bag. Ingredients 2 and 3 were added and mixed with ingredient 1. Ingredients 4 and 5 were mixed with the blend of ingredients 1, 2 and 3 for 20 minutes. The mixture was subjected to compression in a tableting machine having a 0.281x0.625 inch punch under a compression pressure of 5000 psi to make 1000 capsule shaped tablets bisected on one side.
The average weight of the tablets was 717 mg and the thickness was 0.250-0.260 inches.
The hardness, friability and release rate of the 650 mg aspirin tablets were determined as described earlier to give the following results:

Hardness, kg 7.0-9.0 Friability, ~/a 0. 78 Release rate Cumulative Hour % %
l 23.1 23.1 2 36.1 59.2 3 19.7 78~9 4 15.5 94.4 5.2 99.6 Controlled release 650 mg aspirln tablets containing 2.7% Methocel E50 and 6.3% Methocel KlSM were prepared from the untreated hydroxypropylmethylcellyloses with moisture contents in the range of 2-3%.

The 650 mg aspirin tablets were prepared from the following ingredients:

Ingredients grams mg/tablet l Aspirin 650 650 2 Methocel E50 l9.$ 19.5 3 Methocel KlSM 45.5 45.5 4 Lubritab 7 7 Cab~0-Sil M-5 0.5 0.5 The ingre~ients weré mixe~ as described in Example 5.
The mixture was tableted under a compression pressure of 5000 psi using a 0.281x0.625 inch punch to make 1000 capsule shaped tablets bisected on one side.
The average weight of the tablets was 717 mg and the thickness was 0.250-0.260 inches.
The hardness, friability and release rate of -the 650 mg aspirin tablets were determined as described earlier to give the following results:

_ 10 ~ardness, kg 7.5_9.0 Friability, % 0.38 Release rate Cumulative Hour % %
1 1~.7 12.7 2 12.7 25.4 3 13.3 38.7 4 12.5 51.2 15.4 66.6 6 13.4 80.0 7 11.8 91.8 8 6.3 98.1 These results demonstrate that effective release rates are obtained from!mixtures of hydroxypropylmethylcelluloses when at least one of the polymers has a molecular weight above 50.000.

Examples 7-12 describe the preparation of controlled release 300 mg theophylline tablets.

EXAMPI.E 7 Controlled release 300 mg theophylline tablets contain-ing 19.4% Methocel K4M were prepared from untrea-ted Methocel K4M having a moisture content of 2.5%.
The 300 mg theophylline tablets were prepared from the following ingredients:

Ingredients grams mg/tablet _ 10 1 Theophylline, anhydrous 350 306 2 Methocel K4M 37.5 75 3 Cab-O-Sil M-5 0.75 1.5 4 Stearic acid 1.75 3.5 .
Ingredients 1 and 2 were mixed, ingredients 3 and 4 were added and the mixture was then blended for 20 minutes.
Tablets were prepared under a compression pressure of 5000 psi using a 0.300 x 0.545 inch punch to make 500 capsule shaped tablets bisected on one side.
The average weight of the tablets was 392 mg and the thickness was 0.180-0.190 inches.
The hardness, friability and release rates of the 300 mg theophylline tablets were determined in the usual manner to give the following results:

'~

Hardness, kg 6.0-8.0 Friability, % 0.2 -Release rate Cumulative Hour % %
1 19.2% 19.2%
2 12.7 31.9 3 12.3 44.2 4 11.0 55.2 ll.0 66.2 6 11.7 77.9 7 10.0 87.9 8 5.6 93.5 9 6.1 99.6 Controlled release 300 mg theophylline tablets con-taining 19.4% Methocel Kl5M were prepared from untreated Methocel Kl5M having a moisture content of 2.0%.
The 300 mg theophylline tablets were prepared from the following ingredients: -"~

Ingredients grams mg/tablet _ 1 Theophylline, anhydrous 153 306 2 Methocel Kl5M 37.5 75 3 Cab-0-Sil M-5 0.75 1.5 5 ~ Stearic acid 1.75 3.5 The ingredients were mixed as described in Example 7 and tableted under a compression pressure of 5000 psi using a 0.300 x 0.545 inch punch to make 500 capsule shaped -tablets bisected on one side.
The average weight of the table~s was 388 mg and the thickness was 0.180-0.190 inches.
The hardness, friability and release rates of the 300 mg theophylline tablets were determined in the usual manner to give the following results:

15 Hardness, kg 7.5-8.5 Friability, % 0.14 Release rate Cumulative Hour % %
1 17.0 17.0 2 12.8 29.8 3 9.7 39.5 4 8.8 48.3 8.2 56.5 (continued) (continued) 8.2 56.5 6 8.0 64.5 7 7.6 72.1 8 7~1 79.2 9 7.7 86.9 5.4 92.3
11 2.9 95.2
12 3.7 98.9 _ Controlled release 300 mg theophylline tablets con-taining 17.0% Methocel K4M and 7.3% Methocel K15M were prepared from the untreated polymers, each containing 2.0% moisture.
The 300 mg theophylline tablets were prepared from the following ingredients:

. _ Ingredients grams mg/tablet 1 Theophylline, anhydrous306 306 2 Methocel K4M 70 70 3 Met.hoceI K15M 30 30 4 Cab-0-Sil M-5 1.5 1.5 Stearic acid 3.5 3.5 The ingredients were mixed as described in Example 7, adding the premixed Methocel K4M and Methocel KlSM to the theophylline and, a~ter rllixing, adding the excipient in-gredients 4 and 5. Tablets were prepared under 5000 psi pressure using a 0.300 x 0.545 inch punch to make 1000 capsule shaped tablets having an average weight of 406 mg and a thickness o~ 0.193-0.203 inches.
The hardness, friability and release rates were determined as described earlier to give the following results:

-Hardness, kg 4.0-8.0 10 Friability~ % 0.39 ~elease rate Cumulative Hour % %
1 11.4 11.4 2 6.8 18.2 3 7.5 25.7 7.3 33.0 8.4 ~1.4 6 8.9 50.3 7 8.7 59.0 8 11.7 70.7 9 ~.4 75.1 5.9 81.0 11 6.3 87.3 12 8.4 95.7
13 4.4 100.1 -Controlled release 300 mg theophylline tablets con-taining 22.4% Methocel K4M were prepared from Methocel K4M
which was exposed to 85% humidity for 24 hours and then dried at 120F to a moisture content of 4.5%.
The 300 mg theophylline tablets were prepared from the following ingredien~.s:

Ingredients grams mg/tablet 1 Theophylline, anhydrous 612 306 2 Methodel K4M 180 90 3 Cab-0-Sil M-5 3 1.5 4 Stearic acid 7 3.5 The ingredients were mixed as described in Example 7.
The resultant r.lixture was tableted under 5000 psi compression pressure using a 0.300 x 0.5~5 inch punch to make 2000 capsule shaped tablets.
The average weight of the tablets was 400 mg and the thickness was 0.185-0.195 inches.
The hardness, friability and release rates of the 300 mg theophylline tablets were determined in the usual manner to give the following results:

Hardness, kg 5.0-7.0 Friability, /O 0.3 ~ . . ... _ .
Release rate Cumulative Hour % %
1 15.7 15.7 2 11.2 26.9 3 9.6 36.5 ~ 10.9 ~7.4 10.5 57.9 6 10.6 68.5 7 15.5 84.0 8 7.0 91.0 Tablets with 300 mg theophylline, containing 19.4%
of low molecular weight Methocel K35 or Methocel K100, were prepared from untrea-ted Methocel K35 having a number average molecular weight of 19,440 or untreated Methocel K100 having a number average molecular weight of 26,880. The moisture contents of the untreated hydroxypropylmethylcelluloses were in the range of 2-3%.
The 300 mg theophylline tablets were prepared from the following ingredients:

.:,, Ingredlents grams mg/tablet 1 Thoephylline, anhydrous 153 306 2 Methocel K35 or K10037.5 75 3 Cab-0-Sil M-5 0.75 1.5 4. Stearic acid 1~75 3.5 -The ingredients were mixed as described in Example 7 and tableted under 5000 psi pressure using a 0.300 x 0.545 inch punch to make 500 capsule shaped tablets bisected on one side.
The average weight of the Methocel K35 tablets was 390 mg while that of the Methocel K100 tablets was 379 mg. The thickness oE the former tablets was 0.180-0.190 inches while that of the latter tablets was 0.175-0.185 inches.
The hardness, friabili-ty and release rates of the 300 mg theophylline tablets were determined as described earlier to give the following results:

Example No. 11 12 MethoceI K35 K100 Hardness, kg 6.5-8.0 5.4-7.5 Friability, % 0.3 0.2 20 Release rate Cumulative ~ Cumulative Hour % % ';~ % %
1 85.7 85.7 92.8 92.8 2 15.4 101.1 2.8 95.6 t~
These results demonstrate that hydroxypropylmethyl-celluloses having a methoxyl content of 19-24 weight-% are ineffective as the sole component of the carrier base when their number average molecular weight is below 5Q,000.

5Examples 13-1.5 describe the preparation of controlled relea.se 80 mg isosorbide dinitrate tablets.

Controlled release 80 mg isosorbide dinitrate tablets containing 13.5% Methocel K4M and 5.8% Methocel K15M were pre-10 pared from the untreated hydroxypropylmethylcelluloses having moisture contents in the range of 2-3%~
The 80 mg isosorbide dinitrate tablets were prepared from the following ingredients:

Ingredients grams mg/tablet -15 1 Isosorbide dinitrate (25% in lactose) 652.8 326.4 2 Methocel K4M 112 56 3 Methocel K15M 48 24 4 Stearic acid 12 6 29 5 Silica gel (Syloid 244) Registered Trademark 6 3 -Intredients 2 and 3 were premixed and added to ingredient 1. After these ingredients were mixed for 15 minutes, a mixture o~ ingredients 4 and 5, which had passed through a 20 mesh sieve, was added and -the resul-tan-t mixture was blended for 20 minutes. The mlxture was tableted under a pressure o~ 5000 psi using a 0.300 x 0.545 inch punch to prepare 2000 capsule shaped bisected tablets.
The average weight of the tablets was 422 mg and the thickness was 0.182-0.192 inches.
The hardness and ~riability o~ the 80 mg isosorbide dinitrate tablets were determined as described earlier. The release rates were determined using solutions having the pH
indicated in the following table.

Hardness, kg 9.0-11.0 Friability) % 0.15 Release rate Cumulatlve ~our pH % %

1 1.5 15.8 15.8 2 4.5 10.6 26.4 3 6.9 10.5 36.9 4 6.9 8.1 45.0 6.9 7.4 52.4 6 6.9 6.6 59.0 7 7.2 8.0 67.0 8 7.2 5.7 72.7 g 7.2 6.7 79.4 7.2 12.9 92.3 11 7.2 6.2 98.5 i~.~

EXAMPLE 1~

Controlled release 80 mg isosorbide dinitrate -tablets containing 5.8% Methocel K4M and 13.5% Methocel KlSM were pre-pared from the untreated hydroxypropylmethylcelluloses having moisture contents in the range of 2-3%.
The 80 mg isosorbide dinitrate tablets were prepared :Erom the following ingredients:

Ingredients grams mg/tablet 1 Isosorbide dinitrate (25% in lactose) 652.8 326.4 2 Methocel K4M 48 24 3 Methocel K15M 112 56 4 Stearic acid 12 6 Syloid 244 6 3 The ingredients were mixed as described in Example 13.
The mixture was tableted under 6000 psi pressure using a 0.300 x 0.545 înch punch to make 2000 capsule shaped tablets.
The average weight of the tablets was 414 mg and the thickness was 0.180-0.190 inches.
The hardness, friability and release rates of the 80 mg isosorbide dinitrate tablets were determined as described in Example 13 and gave the following results:

Hardness, kg 9.0-12.. 0 Friability, % 0.16 Release rate Cumulative Hour % %
1 11.9 11.9 2 7.6 19.5 3 7.3 26.8 4 7.0 33.8 10.4 44.2 6 9.9 54.1 7 7.8 61.9 8 7.1 69.0 9 6.1 75.1 ~.7 79.8 15 11 3.9 83.7 12 3.5 87.2 13 10.3 97.5
14 3.0 100.5 Controlled release 80 mg isosorbide dinitrate tablets containing 9.6% Methbcel K4M and 9.6% Methocel E4M were pre-pared from the untreated Methocel K4M containing 2.8%
moisture and the untreated Methocel E4M containing 2.5%
moisture.

The 80 mg isosorbide dinitrate tablets were prepared from the following ingredients:

Ingredients grams mg/tablet _ .
1 Isosorbide dinitrate (25~/o in lactose) 326.4 326.4 2 Methocel K4M 40 40 3 Methocel E4M 40 40 4 Stearic acid 6 6 Syloid 244 3 3 10 The ingredients were mixed as described in Example 13.
The mixture was tableted under 6000 psi pressure to make 1000 capsule shaped tablets, using a 0. 300 x 0.545 inch punch.
The average weight of the tablets was 418 mg and the thickness was 0.189-0.195 lnches.
15 The hardness, friability and release rates of the 80 mg isosorbide dinitrate tablets were determined as described in Example 13 and gave the following results:

Hardness, ~g 6.5-8.5 Friability, % 0. 2 20 Release rate Cumulative Hour % %
1 40~7 40.7 2 11.2 51.9 (continued) `` ~ ~ 34 ~

(continued) 3 7.2 59.1 ~ 7.3 66.4 6.7 73.1 6 5.7 78.8 7 7.9 86.7 8 3.5 90.2 9 6.0 96.2 Examples 16-19 descrlbe the preparation of controlled reIease 300 mg lithium carbonate tablets.

Controlled release 300 mg lithium carbonate tablets containing 24.8% Methocel K15M were prepared Erom Methocel Kl5M
which had been exposed to 85% humidity for 24 hours and then dried in a forced air oven at 120F until the moisture content w~s 5.0%.
The 300 mg lithium carbonate tablets were prepared from ~he following ingredients:

-Ingredients grams mg/tablet 1 Lithium carbonate 300 300 2 Methocel K15M 100 100 3 Cherry flavor 1.2 1.2 4 Magnesium stearate 1.6 1.6 Ingredients 1 and 2 were mi.xed, ingredient 3 was added and mixed in, followed by the addition of ingredient 4.
After mixing for 20 minutes:, the mixture was tableted under 5000 psi compression pressure using a 13/32 inch tool to pre-pare 1000 round, flat faced beveled tablets bisected on oneside.
The average weight of the tablets was 395 mg and the thickness was 0.120-0.140 inches.
The hardness and friability of the 300 mg lithium carbonate tablets were determined as described earlier. The release rates were determined using solutions having the pH
indicated in the following table:

-Hardness, kg 6.0-9.0 Friability, % 0.29 _ 15 Release rate Cumulative Cumulative Hour pH % % Hour pH % %
1 1.2 14.2 14.2 13 7.5 3.6 72.5 2 2.5 11.3 25.5 14 7.5 3.9 76.4 3 ~.5 5.6 31.1 15 7.5 3.5 79.9 ~ 7.0 5.4 36.5 16 7.5 3.3 83.2 7.0 5.3 41.8 17 7.5 4.1 87.3 6 7.5 3.9 45.7 18 7.5 2.7 90.0 7 7.5 4.0 49.7 19 7.5 2.5 92.5 8 7.5 3.3 53.0 20 7.5 2.2 94.7 9 7.5 4.2 57.2 21 7.5 2.1 96.8 (continued) (con~inued) 7.5 4.0 61.2 22 7.5 1.7 98.5 11 7.5 3.7 64.9 23 7.5 1.6 lO0.1 12 7.5 ~i.0 68.9 2~ 7.5 1.2 101.3 EX~PLE 17 Controlled release 300 mg lithium carbonate tablets containing 14.2% Methocel K15M were prepared using Methocel K15M
which had been humidified in an 85% humidity chamber and then dried at 120F to a moisture content of 5.0%.
The 300 mg lithium carbonate tablets were prepared from the ~ollowing ingredients:

Ingredients grams mg/tablet 1 Lithium carbonate 300 300 2 MethoceI ~lSM S0 50 3 Cherry flavor 1O2 1.2 4 Magnesium stearate 1.6 1.6 .
The ingredients were mixed as described in Example 16 and the mixture was tableted under a pressure of S000 psi using an 11/32 inch tool to prepare 1000 round, flat beveled tablets.
The average weight of the tablets was 354 mg and the thic~ne,ss was O.lSS-0.165 inches.
The hardness, friability and release rates of the 300 mg lithium carbonate tablets were determined as described in .

Example 16 and gave the following results:

Hardness, kg 3.8-4.0 Friability, V/~ 0.25 Release rate Cumula-tive Hour % %
1 23.3 23.3 2 11.0 34.3 3 10.5 44.8 4 8.5 53.3 8.3 61.6 6 6.8 68.4 7 7.6 76~0 8 5.4 81.4 9 5.3 86.7 4.3 91.0 11 3.2 94.2 12 4.7 98.9 Controlled release 300 mg lithium carbonate tablets containing 19.9% Methocel K15M were prepared using untreated Methocel K15M having a moisture con-tnet of 1.5%

~'J7~

Tlle 300 mg llthium carbonate -tablets were prepared from the ~ollowing ingredients:

-Ingredients grams mg/tablet .
1 Lithium carbonate 300 300 2 Methocel K15M 75 75 3 Magnesium stearate 0.8 0.8 4 Cab-O-Sil M-5 1.0 1.0 The ingredients were mixed as described in Example 16.
An 11/32 inch flat faced bevel tool was used to prepare 1000 white round tablets under 5000 psi pressure. The average weight of the tablets was 380 mg, the thickness was 0.170-0.180 inches and the hardness was 6.0-6.5 kg.

EXA~IPLE 19 Controlled release 300 mg lithium carbonate tablets containing 19.9% Methocel K4M were prepared using untreated Methocel K4M having a moisture content of 2.0%.
The tablets were prepared from the following ingredients:

-Ingredients grams mg/tablet 20 1 Lithium carbonate 300 300 2Methocel K4M 75 75 3Magnesium stearate 0.8 0.8 4 Cab-0-Sil M-5 1.0 1.0 The ingredients were mi~ed as described in Example 16 and the mixture was compressed using an 11/32 inch flat faced bevel tool to prepare 1000 white round table-~s. The average weight of the 300 mg lithium carbona-te tablets was 376 mg, the thickness was 0.165-0.170 inches and the hardness was 6.0 kg.
Examples 20-22 describe the preparation of controlled re]ease nitroglycerin tablets.

Controlled reIease 6.5 mg nitroglycerin tablets con-taining 24% Methocel K4M were prepared from untreated Methocel K4M having a moisture content of 2.5% as well as from Methocel K4M which had been humidiEied and then dried at 120F to a moisture content of 5.0% as described earlier.
Tl~e 6.5 mg nitroglycerin tablets were prepared from the :Eollowing ingredients:

Untreated Treated Methocel K4M Methocel K4M
Ingredients grams grams mg/tablet _ 1 Nitroglycerin (10% in lactose) 350 195 65 2 Lactose, anhydrous 80 120 40 3 Methocel K4M 70 105 35 4 FDC Red No. 3 0.6 0.9 0.3 Stearic acid 6 9 3 6 Syloid 244 2 3 25 7 Cab-0-Sil M-5 2 Ingredients 1, 2, 3 and 4 were mi~ed together and passed through a 20 mesh sieve. Ingredients 5 and 6, and 7 when used, were mixed, passed through a 20 mesh sieve and then mixed with the mixture of the other ingredients. After 20 minutes of blending, the mixture was compressed using a 9/32 inch tool to prepare 2000 pink, round and concave tablets bisected on one side from the untreated Methocel K4M and 3000 similar tablets from the treated Methocel K4M.
The tablets from the untreated Methocel K4M had an average weight of 150 mg and a thickness of 0.135-0.145 inches.
The tablets from the treated Methocel K4M had an average weight of 148 mg and a thickness of 0.130-0.140 inches.
The hardness and friabili-ty of the 6.5 mg nitroglycerin tablets were determined in theusual manner. The release rates were determined using solutions having the same pH as used with the isosorbide dinitrate tablets in Example 13. The results were as follows:

Example No. 20 21 Methocel K4M Untreated Treated .

Hardness, kg 3.0-4.5 3.0-3.5 Friability, % 0.3 0.3 Release rate Cumulative Cumulative Hour % % % %
1 26.6 26.6 23.7 23.7 2 17.5 44.1 1 13.8 37.5 (continued) '~

(contlmled) 3l4.2 58 3 13.350.8 411.6 69.9 18.269.0 510.0 79.9 16.785.7 67.7 87.6 12.~98.1 75.4 93.0 3.8 96.8 -Controlled release 5.5 mg nitroglycerin buccal tablets containing 11.1% Methocel K4M were prepared from untreated Methocel K4M having a moisture content of 1.6%.
The 5.5 mg nitroglycerin buccal tablets were prepared from the following ingredients:

-Ingredients grams mg/tablet 1 Nitroglycerin (10% in lactose) 275 5.5 2 Lactose, anhydrous237.5 47.5 3 MethoceI K4M 35 7 4 Stearic acid 5 Syloid 244 5 20 6 Cab-0-Sil M-5 5 Ingredient 1 was passed through a 20 mesh sieve.

Ingredient 2 was added and mixed, followed by ingredient 3.

A mixture of ingredients 4, 5 and 6 was added ancl mi~ed.
The mixture was compressed using a 1/4 inch concave -tool to prepare 5000 white, round buccal tablets.
The average weight of the tablets was 120 mg, the thickness was 0.130-0.140 inches.

This example describes the preparation of 5.5 mg controlled release phenylpropanolamine base buccal tablets containing 25.8% MethsceI K4M wherein the latter was subjected to humidification in an 85% relative humidity chamber for 24 hours and then dried at 120F to reduce the moisture content to 4.5%.
The 5.5 mg phenylpropanolamine tablets were prepared from the following ingredients:

Ingredients grams mg/tablet 1 Phenylpropanolamine base11 5.5 2 Lactose, anhydrous 100 50 3 MethoceI K4M 40 20 4 Spearmint flavor 1 0.5 20 5 Peppermint flavor 1 0.5 6 Stearic acid 2 Ingredients 1, 2, 4 and 5 were mixed. Ingredient 3 was then added and mixed for 10 minutes. Ingredient 6 was added and the mixture was blended for 20 minutes. The mixture was tableted under S000 psi pressure using a 1/4 inch concave punch to produce 2000 white round buccal tablets.
The average weight of the tablets was 78 mg and the thickness was 0.105-0.110 inches. The hardness, friability and release rates of the buccal -tablets were determined as described in Example 22 and gave the following results:

10 Hardness, kg 4.5-6.0 Friability, % 0.8 Release rate MinutesCumulative %
27.6 39~0 50.0 60.2 73.0 120 83.2 _ This example describes the preparation of controlled release 600 mg potassium chloride lozenges containing 24.8%
untreated Methocel K15M.
The 600 mg lozenges were prepared from the following ingredients:
-4~--Ingredients grams mg/tablet 1Potassium chloride 600 600 2Methocel Kl5M 200 200 3Stearic acid 8 8 .
Ingredient 1 was passed through a 40 mesh sieve.
Ingredient 2 was added and mixed with ingredient 1.
Ingredient 3 was passed through a 40 mesh sieve and then mixed with ingredients 1 and 2 for 20 minutes.
The mixture was compressed under 5000 psi using a 7/16 inch deep concave punch to preparelO00 round mottled white lozenges.
The average weight of the lozenges was 810 mg and the thickness was 0.255-0.265 inches.
The hardness, friability and release rates of the lozenges were determined as described in Example 22 and gave the following results:

Hardness, kg 6.0-8.5 Friability, ~/O 0.13 Release rate Hour Cumulative %
1 71.2 2 87.4 3 99.3 ~r~

Examples 25 to 27 disclose compositions containing anti inflammatory drugs such as ibuprofen, flurbiprofen, diclofenac, indomethacin and naproxen Controlled release 700 mg ibuprofen tablets contain-ing 9.5% Methocel K4M and 9.0% Methocel K15M were prepared from the untreated hydroxypropylmethylcelluloses having moisture contents in the range of 2.0-3.0%.
A tablet having the following composition was pre-pared in the usual manner:

Ingredients mg/tablet 1 Ibuprofen 700 3 MethoceI K4M 85 4 Methocel K15M 80 Syloid 5 6 Stearic Acid The tablets were compressed using 0.750" x 0.300"
capsule-shaped bisected punches at a comprssional force of about 4000 lbs/sq. in. to obtain a tablet of average weight of 893 mg and a hardness of 8 to 10 kg.

Controlled release 200 mg flurbiprofen tablets containing 12.4% Methocel K4M and 10.2% Methocel KlSM were prepared from the untreated hydroxypropylmethylcelluloses having moisture contents in tl~e range of 2~0-3~0~Y
A tablet having the following composition was prepared in the usual manner:

Ingredients mg/tablet 5 1 Fl.urbiprofen 200 2 Methocel K4M 33 3 Methocel K15M 27 4 Stearic Acid 5 Cab-0-Sil M-5 Tablets were compressed using 0.281" x 0.62511 capsule-shaped bisected punches at a compressional pressure of 4000 to 6000 lbs/sq.in. to obtain a tablet of average weight of 270 mg and a hardness of 6 to 8 kg.

15 Controlled release 100 mg diclofenac tablets con-taining 8.5~/o MethoceI K4M and 12.8% Methocel K15M were prepared from the untreated hydroxypropylmethylcelluloses having moisture contents in the range of 2.0-3.0%.
A tablet having the following composition was prepared in the usual manner:

-Ingredients mg/tablet 1Diclofenac sodium 100 2P.V.P. 5 3Methocel K4M 12 25 4 Methocel K15M 18 5Stearic Acid 5 6Cab-O-Sil M-5 Tablets were compressed using 9/32" standard concave round punches at a compressional pressure of 4000 to 6000 lbs/sq.in. to give a tablet weight of 144 mg and a hardness of 6 to 8 kg.

L~.~
The foregoing is exemplary and illustrative of compositions and products responding to the present invention, but it is to be understood that they are not limita-tive since many active medicaments of various types can be employed in the new long-lasting carrier so long as they are absorbable into blood or tissue Erom the general intestinal tract and other bodily surfaces and areas. The medicaments shown in our co-pending application Serial No. 332,348 filed December 18, 1981, now U.S. Patent No. 4,369,172 issued January 18, 1~83, may be used in the practice of the present inven-tion and are incorporated herein by reference. The invention is also intended to cover other dosage forms or forms for application of sustained release ingredients such as vaginal and rectal suppositiories. The lozenges and tablets particularly act on oral, oropharyngeal, pharyngeal and intestinal regions.
The total dosage is governed by usual medical considerations or physicians' directions and when sufficiently large doses of active medicament are incorporated in the unit dosage form, systemic as well as local action is obtained to over-come or control the pathological condition or disorder being treated.

Claims (10)

WHAT IS CLAIMED IS:
1. A carrier base material combined with a therapeutically active medicament and shaped and compressed to a solid unit dosage form having a regular and prolonged release pattern upon administration, the carrier base material being one or more hydroxypropylmethylcelluloses or a mixture of one or more hydroxypropylmethylcelluloses and up to 30% by weight of the mixture of methyl cellulose, sodium carboxymethylcellulose and/or other cellulose ether, and wherein at least one of the hydroxypropylmethylcelluloses has a methoxy content of 16-24 weight-%, a hydroxypropoxyl content of 4-32 weight-% and a number average molecular weight of at least 50,000 and wherein the carrier base material constitutes less than about one third of the weight of the solid unit dosage form.
2. A composition according to claim 1 in which the carrier base material consists of a mixture of one or more hydroxypropylmethylcelluloses and 0-30% sodium carboxy-methylcellulose.
3. A composition according to claim 1 in which the carrier base material consists of a mixture of one or more hydroxypropylmethylcelluloses and 0-30% of methyl-cellulose or other cellulose ether.
4. A composition according to claim 1 in which the active medicament is a moisture sensitive material.
5. A composition according to claim 4 in which the moisture sensitive medicament is selected from but not limited to aspirin, theophylline, phenacetin, procainamide, nikethamide, polymixin, barbiturates, idoxuridine, hydantoins, angiotensinamide, nitroglycerin, isosorbide dinitrate, benzocaine, scopolamine, meperidine, codeine, morphine, streptomycin, ascorbic acid, sulfonamide drugs, tolbutamide, chlorpheniramine, brompheniramine, phenylephrine, diphen-hydramine, penicillins, tropine alkaloids, diethylcarbamizine, dihydroergotamine, caffeine, dexamethasone, and pharmaceutically acceptable salts of any of the above, alkaloid salts and adrenocortical steroid esters.
6. A composition according to claim 1 in which the active medicament is lithium carbonate.
7. A composition according to claim 1 in which the active medicament is phenylpropanolamine.
3. A composition according to claim 1 in which the active medicament is potassium chloride.
9. A composition according to claim 1 in which the active medicament is an anti-inflammatory drug selected from and not limited to ibuprofen, flurbiprofen, diclofenac, indomethacin and naproxen.
10. A method for the preparation of a therapeutically active solid unit dosage form having a regular and prolonged release pattern upon administration, consisting of compressing and shaping a mixture of a therapeutically active medicament and a carrier base material consisting of one or more hydroxy-propylmethylcelluloses or a mixture of one or more hydroxy-propylmethylcelluloses and up to 30% by weight of the mixture of methylcellulose, sodium carboxymethylcellulose or other cellulose ether, and wherein at least one of the hydroxy-propylmethylcelluloses has a methoxyl content of 16-24 weight-%, a hydroxypropoxyl content of 4-32 weight-% and a number average molecular weight of at least 50,000, and wherein the carrier base material constitutes less than about one third of the weight of the solid unit dosage form.
CA000423322A 1982-03-26 1983-03-10 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose Expired CA1188614A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/362,104 US4389393A (en) 1982-03-26 1982-03-26 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US362,104 1982-03-26
BR8300260A BR8300260A (en) 1982-03-26 1983-01-19 PROCESS FOR THE PREPARATION OF HYDROXYPROPYLMETHYL CELLULOSE
AU56761/86A AU583616B2 (en) 1982-03-26 1986-04-28 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose

Publications (1)

Publication Number Publication Date
CA1188614A true CA1188614A (en) 1985-06-11

Family

ID=36910975

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000423322A Expired CA1188614A (en) 1982-03-26 1983-03-10 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose

Country Status (19)

Country Link
US (1) US4389393A (en)
JP (2) JPS58174311A (en)
AR (1) AR230569A1 (en)
AU (1) AU583616B2 (en)
BE (1) BE896136A (en)
BR (1) BR8300260A (en)
CA (1) CA1188614A (en)
CH (1) CH655241A5 (en)
DE (1) DE3309516A1 (en)
DK (1) DK161014C (en)
ES (1) ES520994A0 (en)
FR (1) FR2523845B1 (en)
GB (1) GB2117239B (en)
IL (1) IL68233A (en)
IT (1) IT1171119B (en)
MX (1) MX155695A (en)
NL (1) NL8301042A (en)
SE (1) SE453797B (en)
ZA (1) ZA831817B (en)

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468465A (en) * 1982-09-07 1984-08-28 Sato Clifford S Diagnosing cancer by observing marker glycosaminoglycans extracted from patient
US4591500A (en) * 1983-04-25 1986-05-27 Microencapsulation S.A. Tablet having the shape of a capsule, process and device for its preparation
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
JPH0662404B2 (en) * 1983-06-14 1994-08-17 シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド Controlled-release naproxen and naproxen sodium tablets
JPS6032714A (en) * 1983-08-01 1985-02-19 Teijin Ltd Stabilized powdery pharmaceutical composition for application to nasal mucous membrane
JPS6038322A (en) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd Easily soluble solid preparation containing dihydropyridine-a substance
US4605666A (en) * 1983-10-24 1986-08-12 Basf Corporation Process for preparing spray-dried powders containing a water-soluble vitamin and powders prepared thereby
US4533674A (en) * 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
EP0160087A4 (en) * 1983-10-24 1987-06-29 Basf Wyandotte Corp A process for preparation spray-dried powders containing a water-soluble vitamin and powders prepared thereby.
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
WO1985004100A1 (en) * 1984-03-21 1985-09-26 American Home Products Corporation Sustained release pharmaceutical capsules
WO1985004099A1 (en) * 1984-03-21 1985-09-26 Key Pharmaceuticals, Inc. Sustained release oral dosage form for naproxyn
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US5855908A (en) * 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US5069911A (en) * 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
GB8524135D0 (en) * 1985-10-01 1985-11-06 Sandoz Ltd Darodipine compositions
CH664085A5 (en) * 1985-02-08 1988-02-15 Ciba Geigy Ag PHARMACEUTICAL PREPARATIONS WITH ANALGETIC EFFECTIVENESS AND THEIR PRODUCTION.
US4612345A (en) * 1985-02-28 1986-09-16 The Dow Chemical Company Hydroxypropyl methyl cellulose ethers useful as suspending agents for suspension polymerization of vinyl chloride
EP0198582B1 (en) * 1985-02-28 1990-09-19 The Dow Chemical Company Hydroxypropyl methyl cellulose ethers useful as suspending agents for suspension polymerization of vinyl chloride
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US5783207A (en) * 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
CH666405A5 (en) * 1985-06-24 1988-07-29 Ciba Geigy Ag SOLID, DURABLE PHARMACEUTICAL FORMS WITH ELASTIC FILM COVER.
EP0227814A1 (en) * 1985-07-02 1987-07-08 The Upjohn Company Therapeutic formulations with bimodal release characteristics
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
IT1188212B (en) * 1985-12-20 1988-01-07 Paolo Colombo SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
ES2028074T3 (en) * 1986-06-13 1992-07-01 Alza Corporation ACTIVATION BY MOISTURE OF A TRANSDERMIC PHARMACY SUPPLY SYSTEM.
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4859467A (en) * 1986-09-25 1989-08-22 Colgate-Palmotive Company Sustained release fluoride composition
US4851233A (en) * 1986-10-06 1989-07-25 Warner-Lambert Company Sustained release formulations
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
DE3887179T2 (en) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmaceutical composition, pharmaceutical granules and process for their preparation.
US5071656A (en) * 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4777050A (en) * 1987-03-23 1988-10-11 Schering Corporation Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dexbrompheniramine
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
EP0297866A3 (en) * 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
IT1222414B (en) * 1987-07-31 1990-09-05 Chiesi Farma Spa PHARMACEUTICAL COMPOSITIONS CONTAINING TRAPIDIL, THEIR PREPARATION PROCEDURE AND RELATED THERAPEUTIC USE
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US4861797A (en) * 1987-10-15 1989-08-29 Oratech Pharmaceutical Development Corporation Liquid ibuprofen compositions and methods of making them
US4859704A (en) * 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US4970081A (en) * 1989-01-03 1990-11-13 Sterling Drug Inc. Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US4973470A (en) * 1989-06-26 1990-11-27 Warner-Lambert Company Sustained release pharmaceutical compositions
WO1991002518A1 (en) * 1989-08-25 1991-03-07 Bioglan Laboratories Ltd. Pharmaceutical compositions and a device for administering the same
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5403593A (en) * 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
IT1251114B (en) * 1991-07-26 1995-05-04 Farcon Ag ANTIVIRAL PHARMACEUTICAL FORMS FOR VAGINAL APPLICATION
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
ATE164063T1 (en) * 1991-12-30 1998-04-15 Akzo Nobel Nv THYROACTIVE COMPOSITION WITH CONTROLLED RELEASE
ES2084478T3 (en) * 1992-02-17 1996-05-01 Siegfried Ag Pharma DOSAGE FORMS THAT HAVE PROLONGED RELEASE OF THE ACTIVE INGREDIENT.
US5252577A (en) * 1992-03-06 1993-10-12 Gillette Canada, Inc. Methods of desensitizing teeth
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
EP1826280A3 (en) 1992-09-25 2007-12-05 Boston Scientific Limited Therapeutic conjugates inhibiting vascular smooth muscle cells
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4329794C2 (en) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadol salt-containing drugs with delayed release
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
KR100354702B1 (en) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 Manufacturing method and sustained release composition of pharmaceutical composition
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5660817A (en) * 1994-11-09 1997-08-26 Gillette Canada, Inc. Desensitizing teeth with degradable particles
US5728402A (en) * 1994-11-16 1998-03-17 Andrx Pharmaceuticals Inc. Controlled release formulation of captopril or a prodrug of captopril
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
SI9500173B (en) * 1995-05-19 2002-02-28 Lek, Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US20060068018A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
CA2173818A1 (en) * 1996-04-10 1997-10-11 Francois Chouinard Time-released pharmaceutical compound containing a cured amylose-based support and hydroxypropylmethylcellulose
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
GB9710521D0 (en) 1997-05-22 1997-07-16 Boots Co Plc Process
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
IN186245B (en) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
KR100569763B1 (en) * 1997-10-03 2006-04-11 워너-램버트 캄파니 엘엘씨 Compressed Nitroglycerin Tablet and Its Method of Manufacture
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
SI1064942T1 (en) 1998-03-26 2004-12-31 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparation of a macrolide
AU3024399A (en) * 1998-04-03 1999-10-25 Bm Research A/S Controlled release composition
DE19819012A1 (en) * 1998-04-29 1999-11-25 Dynamit Nobel Ag Fireproof, non-explosive solid mixtures containing nitroglycerin and anhydrous lactose
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
DE19842753A1 (en) * 1998-09-18 2000-03-23 Bayer Ag Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE69934435T2 (en) 1998-10-20 2007-09-27 University Of North Carolina At Chapel Hill METHODS FOR MOISTURIZING THE NOSE CLINIC SKIN
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
AU781048B2 (en) 1999-09-02 2005-05-05 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR101216270B1 (en) 1999-10-29 2012-12-31 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
AR030557A1 (en) * 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
RU2285519C2 (en) * 2000-09-29 2006-10-20 Солвей Фармасьютикалс Б.В. Pharmaceutical composition distinguished by prolonged release independent of ionic force
US6855333B1 (en) * 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
CA2427815C (en) 2000-10-30 2007-07-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003017981A1 (en) 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
EA200400343A1 (en) * 2001-08-29 2004-08-26 Рэнбакси Лабораториз Лимитед COMPOSITION WITH CONTROLLED SURVIVAL OF CLARITROMYCIN OR TINIDAZOL
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
PE20030527A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Extended release compositions comprising as active compound venlafaxine hydrochloride
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US20060159751A1 (en) * 2002-04-11 2006-07-20 Mona Gogia Controlled release pharmaceutical compositions of carbidopa and levodopa
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
DE10224108A1 (en) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol containing sustained-release drug
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
BR0314526A (en) * 2002-10-04 2005-07-26 Pharmacia Corp Pharmaceutical compositions for the treatment of parkinson's disease
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
US20040151772A1 (en) * 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
SI1685829T1 (en) 2002-11-22 2008-08-31 Gruenenthal Gmbh Use of (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol for treating inflammatory pain
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US8298581B2 (en) * 2003-03-26 2012-10-30 Egalet A/S Matrix compositions for controlled delivery of drug substances
DE602004031096D1 (en) * 2003-03-26 2011-03-03 Egalet As MORPHINE SYSTEM WITH CONTROLLED RELEASE
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
SI1663235T1 (en) 2003-08-18 2013-12-31 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
EP2431026A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CN101005830B (en) * 2004-08-13 2010-09-29 贝林格尔·英格海姆国际有限公司 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006031024A1 (en) * 2004-09-15 2006-03-23 Gl Pharmtech Corp. A sustained-release tablet containing doxazosin mesylate
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
ES2409347T3 (en) 2004-10-21 2013-06-26 Aptalis Pharmatech, Inc. Pharmaceutical compositions of masked flavor with gastro-soluble porogenic agents
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE05815688T1 (en) * 2005-01-27 2008-06-26 Alembic Ltd. LEVETIRACETAM FORMULATION WITH EXTENDED RELEASE
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP5336180B2 (en) 2005-05-23 2013-11-06 ナチュラル オータナティブス インターナショナル Compositions and methods for sustained release of β-alanine
JP5161075B2 (en) * 2005-06-03 2013-03-13 エガレット エイ/エス Solid pharmaceutical composition having a first fraction of a dispersion medium and a second fraction of a matrix, wherein the second fraction is first at least partially exposed to gastrointestinal fluid
DE102005028696A1 (en) * 2005-06-21 2006-12-28 Pulmotec Gmbh Use of auxiliary material comprising calcium stearate, magnesium stearate, stearic acid, cromoglycic acid and/or di-sodium-cromoglycate, active substance and carrier material, for adjusting abrasion firmness of hardened preparation
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
KR100753480B1 (en) * 2006-01-27 2007-08-31 씨제이 주식회사 Zaltoprofen-containing sustained release tablet and process for the preparation thereof
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
CN104825397A (en) * 2006-04-03 2015-08-12 伊萨·奥迪迪 Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AU2007254821B2 (en) 2006-06-01 2013-11-14 Bayer Consumer Care Ag Sustained release pharmaceutical formulation comprising phenylephrine
PE20150773A1 (en) * 2006-06-01 2015-05-21 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PHENYLEPHRINE
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
AU2007275034A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
WO2008086804A2 (en) * 2007-01-16 2008-07-24 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
JP2010518021A (en) * 2007-01-31 2010-05-27 メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ Sustained release pharmaceutical formulation of S-adenosylmethionine
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20080287418A1 (en) * 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
MX2009013384A (en) * 2007-06-08 2010-01-25 Addrenex Pharmaceuticals Inc Extended release formulation and method of treating adrenergic dysregulation.
MX2010001260A (en) * 2007-08-03 2010-04-07 Shaklee Corp Nutritional supplement system.
US9763989B2 (en) 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
KR100836960B1 (en) 2007-09-07 2008-06-10 주식회사 서울제약 A novel controlled release-niacin formulation
US8124607B2 (en) 2008-02-26 2012-02-28 Parion Sciences, Inc. Poly aromatic pyrazinoylguanidine sodium channel blockers
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
PT2331210E (en) 2008-09-05 2014-08-25 Gruenenthal Gmbh Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
WO2011023392A1 (en) 2009-08-28 2011-03-03 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic
EP3064064A1 (en) * 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
EP2506836B1 (en) 2009-12-02 2018-02-14 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DK2582366T3 (en) 2010-06-15 2015-12-07 Gruenenthal Gmbh A pharmaceutical combination for the treatment of pain.
WO2012015534A1 (en) 2010-07-28 2012-02-02 Dow Global Technologies Llc A method of controlling the release of an active ingredient from a dosage form
CN103221103B (en) 2010-11-10 2017-05-31 西门子公司 The treatment of contaminated amine solvent due to the entrance of sulfur oxide
CN104873455B (en) 2010-12-22 2023-09-12 普渡制药公司 Coated Tamper Resistant Controlled Release Dosage Forms
US9233073B2 (en) 2010-12-23 2016-01-12 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
DK2665477T3 (en) 2011-01-20 2015-12-14 Bionevia Pharmaceuticals Inc MODIFIED RELEASE COMPOSITIONS OF EPAL REST OR A DERIVATIVE THEREOF AND PROCEDURES FOR USING THE SAME
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
HUE032851T2 (en) 2011-06-27 2017-11-28 Parion Sciences Inc A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
AR086745A1 (en) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE
US20150011549A1 (en) * 2012-02-15 2015-01-08 Takeda Pharmaceutical Company Limited Tablet
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
KR20150059167A (en) 2012-07-06 2015-05-29 에갈렛 리미티드 Abuse deterrent pharmaceutical compositions for controlled release
MX366159B (en) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Self-regulated release of active pharmaceutical ingredient.
LT2931713T (en) 2012-12-17 2017-02-10 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
EA201500742A1 (en) 2013-02-05 2015-12-30 Пердью Фарма Л.П. PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ITMI20132065A1 (en) * 2013-12-11 2015-06-12 Farmatron Ltd THERAPEUTIC RELEASE SYSTEMS MODIFIED FOR ORAL CURCUMIN ADMINISTRATION IN THE TREATMENT OF INTESTINAL DISEASES
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015145459A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
JP7311448B2 (en) * 2020-03-13 2023-07-19 信越化学工業株式会社 Film-forming composition and film

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3839319A (en) * 1973-01-26 1974-10-01 Dow Chemical Co Hydroxypropyl methylcellulose ethers and method of preparation
JPS5163927A (en) * 1974-11-28 1976-06-02 Shinetsu Chemical Co Ketsugoseiryokonajozaihokaizaino seizohoho
AU514195B2 (en) * 1975-12-15 1981-01-29 F. Hoffmann-La Roche & Co. Dosage form
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
DE3309516C2 (en) 1988-03-24
IL68233A (en) 1986-10-31
IT1171119B (en) 1987-06-10
GB2117239B (en) 1987-03-11
IL68233A0 (en) 1983-06-15
DK161014C (en) 1991-10-28
GB2117239A (en) 1983-10-12
JPH0415208B2 (en) 1992-03-17
JPS58174311A (en) 1983-10-13
AR230569A1 (en) 1984-05-31
US4389393A (en) 1983-06-21
MX155695A (en) 1988-04-13
DE3309516A1 (en) 1983-12-01
ES8500740A1 (en) 1984-11-01
GB8307960D0 (en) 1983-04-27
FR2523845A1 (en) 1983-09-30
IT8312471A0 (en) 1983-03-25
JPS61178916A (en) 1986-08-11
AU5676186A (en) 1987-10-29
DK137983D0 (en) 1983-03-25
FR2523845B1 (en) 1986-02-21
US4389393B1 (en) 1985-10-22
CH655241A5 (en) 1986-04-15
AU583616B2 (en) 1989-05-04
SE453797B (en) 1988-03-07
BR8300260A (en) 1984-08-28
SE8301579L (en) 1983-09-27
ZA831817B (en) 1983-12-28
BE896136A (en) 1983-07-01
DK161014B (en) 1991-05-21
DK137983A (en) 1983-09-27
NL8301042A (en) 1983-10-17
SE8301579D0 (en) 1983-03-23
ES520994A0 (en) 1984-11-01

Similar Documents

Publication Publication Date Title
CA1188614A (en) Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
CA1331344C (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
EP0157695B1 (en) Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4369172A (en) Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4695591A (en) Controlled release dosage forms comprising hydroxypropylmethylcellulose
US5451409A (en) Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US4849229A (en) Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
EP0251459B1 (en) Controlled release pharmaceutical composition
US6696085B2 (en) Use of an acrylic type polymer as disintegrating agent
AU741326B2 (en) Rapidly disintegrating methylcellulose tablets
JP2009173687A (en) Phosphate-binding polymer formulation
WO1998001117A1 (en) Sustained release matrix for high-dose insoluble drugs
JPH0513132B2 (en)
JP3884056B1 (en) Method for producing intraoral rapidly disintegrating tablet
EP0284849A1 (en) Sustained release tablets on the basis of high molecular weight hydroxypropylmethylcellulose and a process for their manufacture
US20060182803A1 (en) Oral sustained-release pharmaceutical composition of indapamide, production and use thereof
AU709413B2 (en) Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
MXPA97004043A (en) Assortment of pharmacy of sustained release using a rubber of hydrocoloid in powder obtained from top plants
AU609234B2 (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
CA1111766A (en) Controlled antacid delivery form and method of treatment therewith
AU2004237813B2 (en) Rapidly disintegrating methylcellulose tablets
JP2003183168A (en) Pharmaceutical preparation containing polymer having bonding ability to phosphoric acid
AU1871302A (en) Rapidly disintegrating methylcellulose tablets
MXPA98008340A (en) Spraying module that has a protective element and a recolec element

Legal Events

Date Code Title Description
MKEC Expiry (correction)
MKEX Expiry